arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Benitec Biopharma Inc.

BNTC
$8.66 ▼ -0.65 (-6.98%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Benitec Biopharma Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -6.4% ↘
FCF / Share None
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-12.81M
↓ -45.5% —
FCF / Share Free cash flow per share
$-0.09
↓ -10.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
23
Cash Quality ↓
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 30 quarters